Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Diagenetic evolution of platform carbonates linked to the diapir growth (Central High Atlas, Morocco)

  • Baqués, Vinyet
  • Moragas, Mar
  • Traveset, Anna
  • Vergés Masip, Jaume
  • Martín-Martín, J. D.
  • Saura, Eduard
  • Messager, G.
  • Hunt, David W.
15th Bathurst Meeting of Carbonate Sedimentologists ,13 - 16 July 2015 / Edinburgh, UK, The diagenetic history of strata juxtaposed against diapirs can differ significantly to other basin strata. Key contributing factors are localised uplift, fracturing and brecciation associated with syn- and post-depositional diapiric movements and focused fluid flow along the diapirs flanks during burial. To better understand carbonate diagenesis in diapiric settings, we have studied Jurassic strata flanking the elongate Toumliline (8 km) and Tazoult (22 km) diapirs in the Central High Atlas, Morocco. Similar trends and diagenetic chronology are identified between the two diapirs. During the early growth of the diapir (stage 1), slightly evaporated marine waters circulated along the diapir walls, causing dolomitization of the lower flanking carbonate units. Further active growth of the diapir (stage 2), promoted exposure of the platform, meteoric karstification of the platform carbonates, and the deposition of down-flank syn-diapiric breccias. This is an important step that distinguishes this work from other studies. The continuation of the diapir growth (stage 3) then favoured interaction of the carbonates with mixing marine and meteoric waters, and relates to the dolomitization and calcite cementation of upper flanking carbonate units. After the fossilization of the diapir (stage 4), hydrothermal fluids ascended through dilatant fractures, producing a halo of calcite recrystallization and dolomite cement precipitation. Late karstification of the carbonate deposits are attributed to meteoric fluids circulated during the uplift related to the Tertiary compression (stage 5). The results show a clear influence of diapirism on diagenesis of the flanking carbonates in terms of both the processes and fluids involved. This link between diagenesis and diapirism is generally comparable to those recorded by other authors in La Popa Basin, the South Oman Salt Basin and offshore of Tunisia. This similarity points towards the role of some key fundamental processes., This study is funded by Statoil Research Centre, Bergen (Norway), by the Spanish Ministry of Education and Science (MEC) through the porcets Intramural Especial (CSIC 201330E030), Atiza (CGL2009-1355) and Tecla (CGL2001-26670), CSIC-FSE 2007-2013 JAE-Doc postdoctoral research contract (E.S.), as well as the Group of Sedimentary reserarch of the University of Barcelona (UB).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients, GEMCAD 1602 study

  • Español-Rego, Marta|||0000-0001-5497-2276
  • Fernández-Martos, Carlos
  • Elez, Elena|||0000-0002-4653-6324
  • Foguet, Carles
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Rodríguez, Nuria
  • Ruiz-casado, Ana
  • Pineda, Estela|||0000-0003-2128-747X
  • Cid, Joan|||0000-0001-5445-4508
  • Cabezón, Raquel
  • Oliveres, Helena|||0000-0003-1801-1181
  • Lozano, Miquel|||0000-0003-2593-833X
  • Ginés, Angels
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Ayuso Colella, Juan Ramón|||0000-0002-5306-6850
  • Pagés, Mario
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Torres, Ferran|||0000-0002-7355-7913
  • Thomson, Timothy
  • Cascante, Marta
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Torres, Ferran|||0000-0002-7355-7913
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The online version contains supplementary material available at 10.1007/s00262-022-03283-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.